Presentation is loading. Please wait.

Presentation is loading. Please wait.

Probiotics and Pouchitis What it all about? Dr. Matt. Johnson.

Similar presentations


Presentation on theme: "Probiotics and Pouchitis What it all about? Dr. Matt. Johnson."— Presentation transcript:

1 Probiotics and Pouchitis What it all about? Dr. Matt. Johnson

2 History of the IAPouch 1944 Proctocolectomy + Ileostomy (Strauss + Strauss) 1944 Proctocolectomy + Ileostomy (Strauss + Strauss) 1969 Intra-Abdominal Ileal Reservoir (Kock) 1969 Intra-Abdominal Ileal Reservoir (Kock) 1978 Restorative Proctocolectomy 1978 Restorative Proctocolectomy –(Parks + Nicholls) 1987 J-Pouch Modification 1987 J-Pouch Modification –(Nicholls)

3

4

5 A Normal Pouch A Normal Pouch

6 Pathological changes within a normal Healthy Pouch 6/52 6/52 –plasma cell infiltration –Later = lymphocyte infiltration 6/12 6/12 –Villous atrophy >6/12 >6/12 –Normal adaptation to colonic type mucosa –Tendency to colonic metaplasia

7 Pouch Flora Flora (10x as much bacteria as cells in the body) Flora (10x as much bacteria as cells in the body) 55% of stool = bacteria 55% of stool = bacteria Bacteria feed on undigested food by a process of fermentation Bacteria feed on undigested food by a process of fermentation –Prox jejunum 10 3 (cfu/g of dry weight stool) –Ileum –Pouch –Caecum

8 Pouch Flora The proportion of anaerobes increases distally The proportion of anaerobes increases distally –Ileum = 1:1 (Anaerobe : aerobe) –Caecum = 1000:1 –Ileal Pouch = 100:1 Colonic type flora (bacterioides, bifidobacteria) Colonic type flora (bacterioides, bifidobacteria)

9 Pouchitis Symptoms A) Post Op Stool Frequency A) Post Op Stool Frequency B) Rectal Bleeding B) Rectal Bleeding C) Faecal Urgency* +/- Cramps C) Faecal Urgency* +/- Cramps D) Fever (unusual) D) Fever (unusual) * usually due to inflammation at the distal/efferent limb of the pouch * usually due to inflammation at the distal/efferent limb of the pouch There is often poor correlation between symptoms and either the endoscopic or histology appearance There is often poor correlation between symptoms and either the endoscopic or histology appearance

10 Pouchitis Pouchitis

11 Aetiology of Pouchitis Bacterial profiles are genetically determined and remain stable lifelong Bacterial profiles are genetically determined and remain stable lifelong Response to Antibiotics suggests a pathogenic role for bacteria Response to Antibiotics suggests a pathogenic role for bacteria Diverting ileostomy is therapeutic in CD (recurs 6/12 post re-anastamosis) Diverting ileostomy is therapeutic in CD (recurs 6/12 post re-anastamosis) Pouchitis = Pouchitis = –no difference in number of bacteria (qualitative stool studies) –no difference in type of bacteria (quantitative stool studies) –hightened immunogenicity in UC patients (EGIM of IBD) –loss of tolerance to normal bacteria No longer able to distinguish between normal and pathogenic organisms No longer able to distinguish between normal and pathogenic organisms

12 Clinical Pattern After 6/12 patients fall into 3 catagories; After 6/12 patients fall into 3 catagories; 1) No pouchitis (45%) 1) No pouchitis (45%) 2) Relapsing + Remiting Pouchitis (42%) 2) Relapsing + Remiting Pouchitis (42%) 3) Chronic Pouchitis (13%) 3) Chronic Pouchitis (13%) –> 4/52 –Recurrent courses of antibiotics needed

13 Therapy for Pouchitis There appears to be a bacterial precipitant There appears to be a bacterial precipitant These bacteria appear to be Metronidazole sensitive G- anaerobes These bacteria appear to be Metronidazole sensitive G- anaerobes Antibiotics (Metronidazole or Ciprofloxacin) Antibiotics (Metronidazole or Ciprofloxacin) Probiotics VSL 3 (Gionchetti 1994) Probiotics VSL 3 (Gionchetti 1994) –4x lactobacilli –3x bifidobacteria –1x Strep Salivarius –1x S. thermaphiles Remission can be maintained in 92.5% at 9/12 Vs 0% in the placebo group Remission can be maintained in 92.5% at 9/12 Vs 0% in the placebo group

14 Probiotic Therapeutic Mechanisms Increasing the acidity (increases SCFAs) Increasing the acidity (increases SCFAs) Altering the hosts immune response at the GI mucosa Altering the hosts immune response at the GI mucosa Produce antibiotic like substances (bacteriocins) Produce antibiotic like substances (bacteriocins) Increased IgA + IL 10 (anti-inflammatory) Increased IgA + IL 10 (anti-inflammatory) Decreases IFNg and TNFa (pro-inflammatory) Decreases IFNg and TNFa (pro-inflammatory) Induces T cell shift towards Th2 (anti-inflammatory) Induces T cell shift towards Th2 (anti-inflammatory) May competitively inhibit adherence of potentially pathogenic bacteria May competitively inhibit adherence of potentially pathogenic bacteria Increase intestinal mucosa production Increase intestinal mucosa production Produce SCFAs and vitamins Produce SCFAs and vitamins

15 Bowel Flora and IBD Crohns Crohns –Low bifidobacteria –Low lactobacilli –High E.coli (in active) 1 UC UC –Low lactobacilli (in active) 2 IBD IBD –High bacteriodes/toxins and E.coli (in active) 3 1. Giaffer M.H. et al. The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. Journal of Medical Microbiology 35: Fabia R. et al. Impairment of bacterial flora in human UC and expeimental colitis in the rat. Digestion 54: Swidsinski A. et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 122: 44-54

16 Animal Studies of Probiotics in IBD Prevention Prevention –Lactobacillus reuteri (acetic acid mice) 1 –VSL 3 (IL10 deficient mice) 2 Treatment Treatment –Lactobacilli x2 (methotrexate mice) 3 –Better with oat fibre 1. Fabia, R et al. The effects of exogenous administration o Lactobacillus reuteri R2LC and oat fibre on acetic acid induced colitis in the rat. Scandinavian Journal of Gastroenterology 28: Madsen, K.L et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology Mao Y.S et al. The effects of Lacto bacillus strains and oat fibre on methotrexate induced enterocoliis in rats. Gastroenterology 111:

17 Human Studies of Probiotics in UC UC Treament UC Treament –E.coli Nissle 1917 Vs Mesalazine for 1y 1 Remission = 68% Vs 73% Remission = 68% Vs 73% Relapses = 67% Vs 73% Relapses = 67% Vs 73% –E.coli Nissle 1917 Vs Mesalazine for 1y 2 n= 222 n= 222 Relapses = 36% Vs 33% Relapses = 36% Vs 33% 1. Rembacken B.J. et al. Non-pathogenic E.coli verses mesalazine for the treatment of UC, a randomised trial. Lancet 354: Kruis W. et al. Maintainance of remission in UC is equally effective with E.coli Nissle 1917 as with standard mesalazine. Gastroenterology 120 Suppl. 1:A127 (Abstr. 680)

18 Human Studies of Probiotics in CD E.coli Nissle E.coli Nissle Reduced relapse rate Reduced relapse rate allowed decrease/cessation in steroids allowed decrease/cessation in steroids Mesalazine + yeast Sacchromyces boulardii 2 Mesalazine + yeast Sacchromyces boulardii 2 for 6/12 for 6/12 1/16 relapsed Vs 6/16 on mesalazine alone 1/16 relapsed Vs 6/16 on mesalazine alone 1. Malchow, Helmut A., 1997 Crohns disease and E.coli. Journal of Clinical Gastroenterology 25: Guslandi M. et al. Saccharomyces boulardii in maintainance treatment of Crohns. Digestive Diseases and Sciences 45:

19 Probiotic Trials in Acute Pouchitis High dose of probiotics is effective in the treatment of mild pouchitis. A pilot study. Amanidini C, Gionchetti P et al. Digestive and Liver Disease 2002; 34 (Suppl. 1):A96 Abstract Abstract Positive results Positive results NB = Not written up into a paper ?why NB = Not written up into a paper ?why

20 Probiotic Trials in Chronic Pouchitis Oral bacteriotherapy as maintainance therapy in patients wih chronic pouchitis: a double blind placebo controlled trial. Giochetti P, et al. Gastroenterology 2000; 119: Placebo n = 20 6g VSL 3 n = Patients n = 20 n = 0 n = 3 n = 17 Relapse Remission after 9/12

21 Trials of Probiotics as Prophylaxis Prophylaxis of pouchitis onset with probiotic therapy: a double blind placebo controlled trial. Giochetti P, et al. Gastroenterology 2000; 124: Placebo n = 20 6g VSL 3 n = Patients n = 8 40% n = 12 60% n = 2 10% n = 18 90% Pouchitis Remission after 12/12

22 Probiotics as od Maintainance Once daily high high dose probiotic therapy maintaining remission in recurrent/refractory pouchitis. Mimura T, et al. GUT 2004; 124: Placebo n = 16 6g VSL 3 n = Patients n = 15 93% n = 1 7% n = 2, +1 15% n = 17 85% Pouchitis Remission after 12/12

23 Whats on Offer NameStrainImplantUses Saccaromyces boulardii YesDiarrhoea Prevention + Rx Actimel L.casei strain DN Yes Stoneyfield Yogurt L.reiteriYes Diarrhoea Rx Arla L.acidophilus NCFB 1748 Yes L.rhamnosus VTT E Yes PrimaLiv L.rhamnosus 271 Yes Yakult L.casei strain Shirota Yes Culturelle L.casei GG YesCDT Pro Viva L.plantarum 299v YesIBS

24 Wheres the Future Heading Pre-biotics Pre-biotics –Non-Digestible Food (NDF) ingredients that beneficially effect he host by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon, that can improve host health 1 {Gibson G. 1995}

25 Prebiotics NDOs = Non-Digestible Oligosaccharides 8-15g / d –Average American diet = 5g / d Such CHO – soluble fibre A) Encourages growth of beneficial (saccharolytic) bacteria A) Encourages growth of beneficial (saccharolytic) bacteria B) Attract harmful (proteolytic) bacteria away from mucosa (gut wall) by saturating the adhesin-CHO binding sites B) Attract harmful (proteolytic) bacteria away from mucosa (gut wall) by saturating the adhesin-CHO binding sites Best NDO = Oligosaccharides eg in breast milk Oligofructose increases bifidos x10 1 particularly if low to start (Crohns + UC) 2 particularly if low to start (Crohns + UC) 2 1. Bouhnik Y. et al. Effects of fructo-oligosaccharide indigestion on faecal bifidobacteria and selected metabolic indexes of colon carcinogenesis in healthy humans. Nutrition and Cancer 26: Van Loo J. et al. Functional food properties of non-digestible oligosaccharide: a consensus report from the ENDO project. British Journal of Nutrition 81:

26 Prebiotics Side Effects Flatulence + Bloating Flatulence + Bloating Rx = Gradually increase fibre with time Rx = Gradually increase fibre with time –Gradual increase in Bifidobacterium –Decrease freely available NDF –Decreases gas formed by other bacteria

27 Prebiotics and the Pouch IBD IBD Lactosucrose 8.5g a day for 14/7 Lactosucrose 8.5g a day for 14/7 –Increase Bifidobacteria in 7/7 with IBD Lactulose 1 12 Lactulose 1 12 –Increased lactobacilli –Decreased colitis in mice Pouchitis Pouchitis Inulin 24g a day for 21/7 (crossover trial) 2 12 Inulin 24g a day for 21/7 (crossover trial) 2 12 –Decreased inflammation in 19/19 pouches 1.Madsen L. et al. Lactobacillus species prevent colitis in IL10 gene-deficient mice. Gastroenterology 116: Welters C. et al. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with ileal pouch anal anastamosis. Diseases of the colon and rectum 45:

28 Natural Prebiotics Nutraceuticals = functional foods Nutraceuticals = functional foods Inulin / Fructo-oligosaccharides / Lactulose Transgalacto-oilgosaccharides Inulin / Fructo-oligosaccharides / Lactulose Transgalacto-oilgosaccharides Chicory (boiled root = 90% inulin) Chicory (boiled root = 90% inulin) Jerusalem artichoke Jerusalem artichoke Onion Onion Leek Leek Garlic Garlic Asparagus Asparagus Banana Banana (cereals eg. Oatmeal) (cereals eg. Oatmeal)

29 Natural Prebiotics 1) Isomalto-oligosaccharides (ISO) = Starch 1) Isomalto-oligosaccharides (ISO) = Starch 2) Soyo-oligosaccharides (SOS) = Soya Beans 2) Soyo-oligosaccharides (SOS) = Soya Beans 3) Xylo-oligosaccharides (XOS) = corn cobs 3) Xylo-oligosaccharides (XOS) = corn cobs 4) Lactosucrose (LS) = artificial sweeteners 4) Lactosucrose (LS) = artificial sweeteners


Download ppt "Probiotics and Pouchitis What it all about? Dr. Matt. Johnson."

Similar presentations


Ads by Google